SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it will implement a reverse stock split of its ordinary shares at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split was approved by the Company’s Board of Directors in accordance with British Virgin Islands law. The Reverse Stock Split will take effe ...

Group 1 - The price target for EUDA Health has been lowered from $6 to $2.75 while maintaining a Buy rating on the shares [1] - The revenue estimate for EUDA Health has been revised down to $27.23 million from $43.05 million due to a reduction in Helixe bottles sold in 2026, decreasing from 105,000 to 50,000 [1] - The issuance of 12.5 million shares in late February has had a dilutive effect on the company's EPS estimates [1]

Investment Rating - The report maintains a "Buy" rating for EUDA Health Holdings Limited with a target price of $2.75, down from a previous target of $6.00 [10]. Core Insights - EUDA has made significant progress in expanding its stem cell business, transitioning from a third-party distributor to a vertically integrated stem cell therapy company capable of rapid growth in China [10]. - Despite delays in the Helixé product's progress leading to a downward revision of short-term revenue forecasts, the management's focus on building a portfolio of longevity and health products remains attractive for long-term growth [10]. - The revenue forecast for 2026 has been adjusted down to $27.23 million, reflecting a significant impact from the issuance of new shares and a reduction in expected Helixé product sales from 105,000 bottles to 50,000 bottles [9][10]. Market Data - Current stock price is $0.73 with a market capitalization of $36.73 million [1]. - The company has a 52-week trading range of $0.70 to $4.30 and an average daily trading volume of 523,000 shares [1]. - Institutional ownership is at 2%, while insider ownership stands at 37% [1]. Financial Overview - The company reported cash of $0.17 million, short-term debt of $2.06 million, and a long-term debt of $0.00 million [1]. - The EBITDA for the past 12 months is reported at $(1.85) million, indicating ongoing operational losses [1]. Business Expansion - In January 2026, EUDA agreed to a RMB 6 million convertible loan to upgrade its cGMP production facilities in Shenzhen, aimed at creating an advanced center for stem cell therapy [2]. - The company has launched a nationwide stem cell extraction, cryopreservation, and clinical delivery platform in collaboration with Inno and Wuhan Kane Hospital [3]. - EUDA has also entered the Malaysian market with a direct selling license and is exploring opportunities in India through a partnership with SafeRock India Private Limited [7]. Product Development - The upgraded EUDA Helixé 2.0 product was launched in January 2026, focusing on long-term health and anti-aging, and has received Halal certification for global marketing [6]. - The sales forecast for the Helixé product has been revised down due to adjustments in marketing activities, with management still confident in achieving a long-term sales target of 500,000 bottles [6]. Token Integration - EUDA plans to launch a utility cryptocurrency called "QB" to create a token-based digital health and rewards platform, aiming to enhance user loyalty and integrate decentralized finance with healthcare [8].

Investment Rating - The report maintains a "Buy" rating for EUDA Health Holdings Limited with a target price of $2.75, down from a previous target of $6.00 [10]. Core Insights - EUDA has made significant progress in expanding its stem cell business, transitioning from a third-party distributor to a vertically integrated stem cell therapy company capable of rapid growth in China [10]. - Despite delays in the Helixé product's progress leading to a reduction in short-term revenue forecasts, the management's focus on building a portfolio of longevity and health products remains attractive for long-term growth [10]. - The revenue forecast for 2026 has been adjusted down to $27.23 million, reflecting a decrease in expected sales of the Helixé product from 105,000 bottles to 50,000 bottles [9][10]. Market Data - Current stock price is $0.73 with a market capitalization of $36.73 million [1]. - The company has a 52-week trading range of $0.70 to $4.30 and an average daily trading volume of 523,000 shares [1]. - Institutional ownership is at 2%, while insider ownership stands at 37% [1]. Financial Overview - The company reported cash of $0.17 million, short-term debt of $2.06 million, and a long-term debt of $0.00 million [1]. - The EBITDA for the past 12 months is $(1.85) million, and the operating cash flow is $(1.99) million [1]. - Revenue projections for 2023, 2024, and 2025 are $3.71 million, $4.01 million, and $9.23 million respectively [1]. Business Expansion - In January 2026, EUDA agreed to a convertible loan of 6 million RMB to upgrade its cGMP production facilities in Shenzhen, aimed at creating an advanced center for stem cell therapy [2]. - The company has launched a nationwide stem cell extraction, cryopreservation, and clinical delivery platform in collaboration with Inno and Wuhan Kane Hospital [3]. - EUDA has also obtained a direct selling license in Malaysia and entered the Indian market through a partnership with SafeRock India Private Limited [7]. Product Development - The upgraded EUDA Helixé 2.0 product was launched in January 2026, featuring a smaller capsule size and enhanced formulation targeting long-term health and anti-aging [6]. - The product has received Halal certification, allowing it to be marketed to the global Muslim market [6]. Token Integration - In December 2025, EUDA announced plans to create a token-based digital health and rewards platform using a utility cryptocurrency named "QB" [8]. - The QB token is expected to facilitate payments, rewards, and access to EUDA's products and services, enhancing user loyalty to its ecosystem [8].

Core Viewpoint - EUDA Health Holdings Limited has successfully repurchased and cancelled a warrant previously issued to Streeterville Capital, LLC, eliminating potential share dilution and enhancing its financial position [1][3]. Group 1: Warrant Background - The warrant was part of a securities purchase agreement dated November 26, 2025, allowing for the purchase of up to 2,000,000 newly issued ordinary shares [2]. - The warrant underwent amendments on December 16, 2025, and January 13, 2026, prior to its repurchase [2]. Group 2: Repurchase Details - The total purchase price for the warrant repurchase was US$125,000, and the warrant has been fully cancelled, with no remaining warrants under this agreement [3]. - This transaction has completely eliminated the potential issuance of shares associated with the warrant [3]. Group 3: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [4]. - The company aims to lead in the non-invasive and preventive healthcare sector, addressing the needs of over 1.8 billion people in a region with significant demographic shifts, including a rapidly aging population [4]. - EUDA is committed to transforming healthcare from reactive treatment to proactive, longevity-focused care, supported by innovative and science-backed health solutions [4].

Core Viewpoint - EUDA Health Holdings Limited has amended its warrant agreement with Streeterville Capital, reducing the exercise price and minimum closing price for forced exercise, aligning with current market conditions while maintaining its long-term strategy [1][2][3] Group 1: Warrant Amendment Details - The exercise price of the warrant has been reduced from US$4.00 per share to US$2.00 per share [2] - The minimum closing price required to trigger a forced exercise has been lowered from US$6.00 to US$3.00 [2] - All other terms of the warrant remain unchanged [2] Group 2: Company Overview and Strategy - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [3] - The company aims to address the healthcare needs of over 1.8 billion people in the region, with a strategic focus on the longevity sector [3] - EUDA is committed to transforming healthcare from reactive treatment to proactive, longevity-focused care through innovative and accessible health solutions [3]

Core Viewpoint - EUDA Health Holdings Limited has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd to support the upgrade of Shenzhen Inno's cGMP facility, enhancing EUDA's regenerative medicine capabilities in China [1][3]. Investment Details - EUDA plans to invest up to RMB 6 million in two tranches: an initial tranche of RMB 1 million and a second tranche of RMB 5 million, contingent on due diligence and regulatory approvals [2]. - The investment is structured as a convertible loan note with a 6% annual interest rate, payable semi-annually, and may be redeemed with accrued interest if not converted [4]. Facility and Technology Development - Shenzhen Inno will utilize the capital to upgrade its facility in Shenzhen, creating a state-of-the-art production and innovation center for stem cell treatments, which will serve as a core technology hub for EUDA's strategy in China [3]. - The facility will support international collaborations and provide a replicable platform for expansion into additional cities and markets [3]. Company Background - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [8]. - The company aims to lead the transformation of regional healthcare from reactive treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [8]. Strategic Vision - The CEO of EUDA emphasized that the agreement reflects a disciplined approach to building long-term stem cell therapy platforms, aiming for deeper ownership and integration over time [7].

Core Viewpoint - EUDA Health Holdings Limited has amended its warrant agreement with Streeterville Capital, reducing the exercise price and minimum closing price for forced exercise, which may enhance the attractiveness of the warrant for investors [3]. Group 1: Warrant Transaction Background - On November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital for a warrant exercisable into up to 2,000,000 newly issued ordinary shares for an aggregate purchase price of US$100,000 [2]. - The warrant was issued on December 4, 2025, and can be exercised for cash for 90 days from the issuance date, after which a cashless exercise will occur if not exercised [2]. Group 2: Amended Terms - The Warrant Amendment, effective December 16, 2025, reduces the exercise price from US$6.00 to US$4.00 per share [3]. - The minimum closing price required to trigger a "Forced Exercise" has been reduced from US$7.50 to US$6.00 [3]. Group 3: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [4]. - The company aims to address the healthcare needs of over 1.8 billion people in the region, with a strategic focus on the growing longevity sector [4]. - EUDA is positioned to transform regional healthcare from reactive treatment to proactive, longevity-focused care [4].

Core Company Developments - EUDA Health Holdings Limited has launched a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, partnering with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital to expand its clinical and logistics network [1] - The platform represents a significant advancement in EUDA's stem cell strategy, enhancing capabilities in cell extraction, processing, cryogenic storage, logistics, and clinical application [1] Platform Design Principles - The platform is built on three core principles: centralized processing with decentralized access, long-term cell preservation for future clinical use, and integration with longevity medicine [2] Infrastructure and Capacity - Shenzhen Inno Immune Co., Ltd. serves as the primary cell processing and cryogenic storage hub in Southern China, with an initial capacity for approximately 50,000 patient cell units [3] - Wuhan Kaien Hospital is designated as the Central China clinical and longevity flagship, with a planned capacity to support around 200,000 patient cell units, integrating various health management services [4] Clinical Access and Logistics - EUDA collaborates with Guangdong Wanhai Cell Biotechnology Co., Ltd. and Shunfeng Cold Chain Logistics Co., Ltd. to establish a nationwide clinical access layer and ensure regulated transport of biological materials [6][8] - The integrated structure allows for stem cell extraction at local clinics, with subsequent processing and storage at designated facilities, ensuring quality control and scalability [8] Strategic Vision - The CEO of EUDA emphasized the transformation of regenerative medicine access in China through a coordinated national system that connects extraction, storage, logistics, and clinical delivery [9] - EUDA aims to lead the non-invasive and preventive healthcare market in Asia, addressing the healthcare needs of over 1.8 billion people in a rapidly aging population [10]

Core Insights - EUDA Health Holdings Limited is set to launch EUDA Helixé 2.0 in January 2026, representing a significant upgrade in its premium vitality and longevity supplement line [1][6] Product Enhancements - The new formulation includes a 20% increase in New Zealand sourced deer placenta powder, raising the dosage from 100 mg to 120 mg, enhancing its potency [2] - L-glutathione has been replaced with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent) to improve antioxidant stability and support skin health [2] - Advanced encapsulation technology has been implemented to enhance stability, absorption efficiency, and shelf life, utilizing a nano-based delivery system for smaller capsule sizes [3][8] Packaging and Design - A new proprietary bottle design has been introduced to reflect the premium positioning of EUDA Helixé, enhancing product protection and brand identity [4] Market Expansion - EUDA Helixé 2.0 has received New Zealand Halal certification, facilitating broader international distribution and entry into Muslim markets across Southeast Asia and the Middle East [5] Strategic Positioning - The launch of EUDA Helixé 2.0 underscores the company's commitment to innovation and global wellness solutions, positioning it as a core offering within EUDA's health and longevity ecosystem [6][7] - The company aims to address the healthcare needs of over 1.8 billion people in Asia, focusing on the growing longevity sector as populations age [9]